CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines. It possesses five integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination, formulation and mRNA www.cansinotech.com

Location
Canton
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2022
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in